Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
Authors
Discussion
Loading...
Member takes
Implication
Randomized trial shows significant weight loss with semaglutide in obesity, suggesting potential for lasting impact.
Key Points
- Clinically significant weight loss of −10.2% was observed at 208 weeks with semaglutide.
- Weight loss was sustained over 65 weeks and maintained for up to 4 years.
- Assessment of participants demonstrated improved anthropometric outcomes and safety measures with semaglutide use in various BMI categories, reducing serious adverse events rates as compared to placebo results over time for each group observed at 100 years per events rate. 44.23 vs. 50.48 among <30 kg/m² group shows difference in patterns observed in different weight classifications contributing to results analysis and effectiveness study across different population categories reviewed.
Cite This Study
Ryan et al. (2024) studied this question.